Champion Iron reports steady Q3 operational performance with improved costs and significant progress on its high-grade DRPF project. The company also details the fully-financed plan to acquire Norway's Rana Gruber, aiming to strengthen its foothold in the European steelmaking market.
Valero Energy reported a robust fourth quarter, with net income surging to $1.1 billion, driven by strong refining margins and record operational performance. While renewable diesel faced headwinds, ethanol profits soared. The company outlined disciplined capital plans and highlighted potential tailwinds from policy clarity and increased access to discounted heavy crude.
A sharp sell-off triggered by broad crypto market weakness pushed XRP below key support levels, with traders now eyeing $1.74 as a critical near-term floor and the $1.79–$1.82 range as the next major resistance hurdle.
Bitcoin's volatility gauge spiked sharply during Thursday's sell-off, signaling heightened trader anxiety and a rush for downside protection, though metrics suggest the market is not yet in extreme fear territory.
A new industry report reveals Latham & Watkins advised on a record $370bn in tech, media, and telecom deals last year, narrowly edging out rivals in a highly competitive legal advisory market.
Once crypto miners, IREN and Applied Digital have pivoted to AI infrastructure, delivering staggering returns. But as valuations soar, investors face a critical choice between predictable cash flow and high-growth optionality.
Amidst market volatility, Coca-Cola (KO) stands out with its formidable brand moat and a 63-year dividend growth streak, offering investors a blend of stability and reliable income.
Cisco Systems has inked a major 15-year virtual power purchase agreement for solar energy in Poland, a move that extends its environmental commitments into one of Europe's more fossil-fuel-dependent grids and underscores its long-term capital allocation strategy beyond core tech.
A fresh round of analyst price target adjustments for European asset manager Amundi (ENXTPA:AMUN) is prompting investors to recalibrate their expectations, placing renewed scrutiny on the firm's growth trajectory in a challenging macroeconomic climate.
Cardinal Energy Ltd. (TSX:CJ) has successfully upsized its bought deal financing to CA$95.15 million, capitalizing on robust investor appetite. The proceeds are earmarked to accelerate development of its key Reford 2 thermal oil project and strengthen its balance sheet, even as its valuation metrics present a complex picture for investors.
DuPont de Nemours launches a new ion exchange resin designed to boost productivity for organic acid producers in food, pharma, and bioplastics, as its stock shows sustained momentum.
Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.
Southside Bancshares (SBSI) reported a significant rebound in fourth-quarter earnings, driven by strategic repositioning of its securities portfolio and lower funding costs. While loan growth remained modest, executives outlined a cautious outlook for near-term margin improvement and detailed plans for technology investments and selective M&A in competitive Texas markets.
Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
Investment bank Macquarie has lowered its price target for Chinese EV maker XPeng, pointing to reduced government subsidies and a complex path to profitability as the company expands its model lineup.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
Analysts at Stifel have initiated coverage on sports data giant Sportradar Group AG (NASDAQ: SRAD) with a Buy rating and a $28 price target, citing its dominant market position and favorable industry dynamics as online sports betting consolidates.
UBS has increased its price target for digital transformation leader Globant to $75, forecasting a period of stabilized, if modest, growth for the IT services sector next year despite near-term revenue headwinds.
With key self-assessment deadlines approaching, property investors must navigate a changed landscape of tax reliefs and allowable expenses to minimise their liabilities. Experts urge early preparation to avoid costly surprises.
